Factors influencing the development of lipodystrophy in human immunodeficiency virus infected patients

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 5, 2003, Pages 339-340

  Collazos, Julio ^a   Rodriguez Guardado, Azucena ^b   Maradona, Jose A ^b   Mayo, Jose ^a   Asensi, Victor ^b   Ibarra, Sofía ^a   Carton, Jose A ^b   Casado, Luis ^b  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION;

ADULT; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; LIPODYSTROPHY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RISK FACTORS; SEX DISTRIBUTION; SPAIN; TIME FACTORS;

EID: 0038793418     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310008393     Document Type: Article

References (12)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
2. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
3. Savés M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396-405.
4. Zylberberg H, Nalpas B, Pol S, Bréchot C, Viard JP. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS 2000; 14: 2055.
5. Torti C, Patroni A, Tinelli C, Sleiman I, Quirós-Roldán E, Puoti M, Castelli F. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 315-7.
6. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-50.
7. Rodriguez-Guardado A, Maradona JA, Asensi V, Carton JA, Casado L. Hepatitis C in patients with HIV infection and lipodystrophy. J Acquir Immune Defic Syndr 2003; 32: 348-9.
8. Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients. The protective effect of hepatitis C virus coinfection. AIDS 2003; 17: 927-9.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
10. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-71.
11. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792-6.
12. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261: 159-65.